Sanofi says Gaucher pill meets goals in late-stage tests

PARIS Fri Feb 15, 2013 11:32am EST

Related Topics

PARIS Feb 15 (Reuters) - Sanofi said on Friday its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

If approved, eliglustat tartrate could become the first-oral treatment for Gaucher disease, a rare genetic disorder affecting some 10,000 patients worldwide.

(Reporting by Elena Berton; Editing by Christian Plumb)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.